27567951|t|Hypo-Vascular Liver Metastases Treated with Transarterial chemoembolization: Assessment of Early Response by Volumetric Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging
27567951|a|To evaluate the value of anatomic and volumetric functional magnetic resonance imaging (MRI) in early assessment of response to trans-arterial chemoembolization (TACE) in hypovascular liver metastases. This retrospective study included 52 metastatic lesions (42 targeted and 10 non-targeted) in 17 patients who underwent MRI before and early after TACE. Two reviewers reported response by anatomic criteria (Response Evaluation Criteria in Solid Tumor [RECIST], modified RECIST [mRECIST], and European Association for the Study of Liver Disease [EASL]) and functional criteria (volumetric apparent diffusion coefficient and contrast enhancement). treatment endpoint was RECIST at 6 months. A 2-sample paired t test was used to compare the mean changes after intra-arterial therapy. P < .05 was considered statistically significant. Reduction in mRECIST and EASL at 1 month was significant in the whole cohort as well as in responders by RECIST at 6 months, and the changes fulfilled partial response criteria for both metrics in responders. Responders also had significant changes in volumetric apparent diffusion coefficient (P = .01 and P = .03) and contrast enhancement (P < .0001 and P < .0001) at 1 month for both readers, respectively. At 1 month post treatment, responders did not fulfill RECIST criteria but fulfilled mRECIST and EASL criteria. In addition, volumetric contrast-enhanced and diffusion-weighted MRI may be helpful in evaluating early treatment response after TACE in hypovascular liver metastases in patients who have failed to respond to initial chemotherapy.
27567951	0	13	Hypo-Vascular	T033	C1287688
27567951	14	30	Liver Metastases	T191	C0494165
27567951	31	43	Treated with	T061	C0332293
27567951	44	75	Transarterial chemoembolization	T061	C3539919
27567951	77	87	Assessment	T058	C0220825
27567951	91	96	Early	T079	C1279919
27567951	97	105	Response	T201	C0521982
27567951	109	119	Volumetric	T082	C0445383
27567951	120	137	Contrast-Enhanced	T060	C1707501
27567951	142	187	Diffusion-Weighted Magnetic Resonance Imaging	T060	C0598801
27567951	213	221	anatomic	T080	C0220784
27567951	226	236	volumetric	T082	C0445383
27567951	237	247	functional	T169	C0205245
27567951	248	274	magnetic resonance imaging	T060	C0024485
27567951	276	279	MRI	T060	C0024485
27567951	284	289	early	T079	C1279919
27567951	290	312	assessment of response	T201	C0521982
27567951	316	348	trans-arterial chemoembolization	T061	C3539919
27567951	350	354	TACE	T061	C3539919
27567951	359	371	hypovascular	T033	C1287688
27567951	372	388	liver metastases	T191	C0494165
27567951	395	414	retrospective study	T062	C0035363
27567951	427	445	metastatic lesions	T033	C1513183
27567951	450	458	targeted	T098	C0039309
27567951	486	494	patients	T101	C0030705
27567951	509	512	MRI	T060	C0024485
27567951	513	519	before	T079	C0332152
27567951	524	529	early	T079	C1279919
27567951	536	540	TACE	T061	C3539919
27567951	546	555	reviewers	T098	C1882950
27567951	565	573	response	T201	C0521982
27567951	577	585	anatomic	T080	C0220784
27567951	586	594	criteria	T078	C0243161
27567951	596	639	Response Evaluation Criteria in Solid Tumor	T170	C1709926
27567951	641	647	RECIST	T170	C1709926
27567951	650	665	modified RECIST	T170	C1709926
27567951	667	674	mRECIST	T170	C1709926
27567951	681	732	European Association for the Study of Liver Disease	T093	C0596660
27567951	734	738	EASL	T093	C0596660
27567951	745	755	functional	T169	C0205245
27567951	756	764	criteria	T078	C0243161
27567951	766	776	volumetric	T082	C0445383
27567951	777	807	apparent diffusion coefficient	T077	C3890194
27567951	812	832	contrast enhancement	T080	C2985747
27567951	835	844	treatment	T061	C0087111
27567951	845	853	endpoint	T080	C2349179
27567951	858	864	RECIST	T170	C1709926
27567951	880	902	2-sample paired t test	T170	C1709451
27567951	915	922	compare	T052	C1707455
27567951	932	939	changes	T169	C0392747
27567951	946	968	intra-arterial therapy	T061	C3865755
27567951	993	1018	statistically significant	T081	C0237881
27567951	1020	1029	Reduction	T061	C0441610
27567951	1033	1040	mRECIST	T170	C1709926
27567951	1045	1049	EASL	T093	C0596660
27567951	1065	1076	significant	T078	C0750502
27567951	1090	1096	cohort	T098	C0599755
27567951	1111	1121	responders	T033	C0919876
27567951	1125	1131	RECIST	T170	C1709926
27567951	1171	1187	partial response	T201	C0521982
27567951	1188	1196	criteria	T078	C0243161
27567951	1217	1227	responders	T033	C0919876
27567951	1229	1239	Responders	T033	C0919876
27567951	1249	1260	significant	T078	C0750502
27567951	1261	1268	changes	T169	C0392747
27567951	1272	1282	volumetric	T082	C0445383
27567951	1283	1313	apparent diffusion coefficient	T077	C3890194
27567951	1441	1455	post treatment	T079	C2709088
27567951	1457	1467	responders	T033	C0919876
27567951	1476	1483	fulfill	T067	C1550543
27567951	1484	1490	RECIST	T170	C1709926
27567951	1491	1499	criteria	T078	C0243161
27567951	1514	1521	mRECIST	T170	C1709926
27567951	1526	1530	EASL	T093	C0596660
27567951	1531	1539	criteria	T078	C0243161
27567951	1541	1552	In addition	T169	C0332287
27567951	1554	1564	volumetric	T082	C0445383
27567951	1565	1582	contrast-enhanced	T060	C1707501
27567951	1587	1609	diffusion-weighted MRI	T060	C0598801
27567951	1639	1644	early	T079	C1279919
27567951	1645	1663	treatment response	T201	C0521982
27567951	1670	1674	TACE	T061	C3539919
27567951	1678	1690	hypovascular	T033	C1287688
27567951	1691	1707	liver metastases	T191	C0494165
27567951	1711	1719	patients	T101	C0030705
27567951	1750	1771	initial chemotherapy.	T061	C3665472